Is Aarti Pharma overvalued or undervalued?

Jun 09 2025 04:41 PM IST
share
Share Via
As of May 12, 2025, Aarti Pharma is considered undervalued with a valuation grade of very attractive, featuring a PE Ratio of 30.27, an EV to EBITDA of 18.53, a ROCE of 16.08%, and a year-to-date return of 32.76%, outperforming the Sensex's 5.56%.
As of 12 May 2025, Aarti Pharma's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 30.27, an EV to EBITDA of 18.53, and a ROCE of 16.08%.

In comparison with peers, Aarti Pharma's PE Ratio is lower than that of Sun Pharmaceutical Industries Ltd., which stands at 35.25, and Divi's Laboratories Ltd., which has a PE Ratio of 79.33, both of which are categorized as expensive. Additionally, Aarti Pharma's PEG Ratio of 1.18 suggests that its growth prospects are reasonably priced compared to its earnings growth. Notably, Aarti Pharma has outperformed the Sensex, with a year-to-date return of 32.76% compared to the Sensex's 5.56%, reinforcing its attractive valuation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News